Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus

BACKGROUND: Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia. Linagliptin is a glucose-lowering agent of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class that is of particular interest for the prevention of accelerated cognitive decline, because...

Descripción completa

Detalles Bibliográficos
Autores principales: Biessels, Geert Jan, Janssen, Jolien, van den Berg, Esther, Zinman, Bernard, Espeland, Mark A., Mattheus, Michaela, Johansen, Odd Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769408/
https://www.ncbi.nlm.nih.gov/pubmed/29334906
http://dx.doi.org/10.1186/s12883-018-1014-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769408/
https://www.ncbi.nlm.nih.gov/pubmed/29334906
http://dx.doi.org/10.1186/s12883-018-1014-7

Ejemplares similares